# Zalutumumab in Non-curable Patients With SCCHN

> **NCT00542308** · PHASE2 · COMPLETED · sponsor: **Genmab** · enrollment: 90 (actual)

## Conditions studied

- Head and Neck Cancer
- Squamous Cell Cancer

## Interventions

- **DRUG:** Zalutumumab

## Key facts

- **NCT ID:** NCT00542308
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542308, "Zalutumumab in Non-curable Patients With SCCHN". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00542308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*